Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
105 participants
INTERVENTIONAL
2018-05-07
2019-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ultrasound-guided QLB will be performed on the side of surgery with 0.375% ropivacaine solution (0.2 mL per kg).
Every patient will get patient-controlled analgesia pump with oxycodone in the postoperative period.
Postoperative pain will be measured with VAS (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of the operation. 24 -hours period.
At the 1, 3, 6 months patients will be interviewed by phone to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QLB
At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
QLB
On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
PCA
Patient-controlled analgesia
GA
General anesthesia
Oxycodone
administered by PCA
Sevoflurane
Inhalational anesthetic during GA
Fentanyl
painkiller during GA
Rocuronium
muscle relaxant during GA
Control
Standard care. No regional blocks.
PCA
Patient-controlled analgesia
GA
General anesthesia
Oxycodone
administered by PCA
Sevoflurane
Inhalational anesthetic during GA
Fentanyl
painkiller during GA
Rocuronium
muscle relaxant during GA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QLB
On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
PCA
Patient-controlled analgesia
GA
General anesthesia
Oxycodone
administered by PCA
Sevoflurane
Inhalational anesthetic during GA
Fentanyl
painkiller during GA
Rocuronium
muscle relaxant during GA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* nephrectomy procedure
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów
UNKNOWN
Department of Anesthesiology and Intensive Care, J. Śniadecki Hospital in Białystok
UNKNOWN
Medical University of Lublin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michał Borys
M.D., Ph.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Intensive Care, J. Śniadecki Hospital in Białystok
Bialystok, , Poland
Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów
Rzeszów, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KE-0254/328/2017
Identifier Type: -
Identifier Source: org_study_id